Biotechnology

MAIA Biotech

MAIA Biotech released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1408 (forecast USD -0.18)

MAIA Biotech released FY2025 Q4 earnings on March 23 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0975 (forecast USD -0.13)

MAIA Biotech released FY2025 Annual Earnings on March 23 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7 (forecast USD -0.74)

MAIA Biotechnology Closes $2.25M Private Placement with Qualified Investors

Noble Financial Analyst Reiterates Buy Rating on MAIA Biotechnology Stock

MAIA Biotechnology Completes $1.51 Million Private Placement

MAIA Biotech Initiates Phase III Clinical Trial of Ateganosine

Stan Smith Buys MAIA Biotechnology Stocks

MAIA Biotechnology CEO Vitoc Vlad Buys 10,500 Shares

MAIA Biotech released FY2025 9 Months Earnings on November 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.6077

MAIA Biotech released FY2025 Q3 earnings on November 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2699 (forecast USD -0.19)

MAIA Biotechnology Inc. Raises Funds Through Private Placement

MAIA Biotech released FY2025 Semi-Annual earnings on August 11, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.34

MAIA Biotech released FY2025 Q2 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1799 (forecast USD -0.24)

MAIA Biotechnology Releases Preclinical Data on Second-Generation Ateganosine Prodrug

MAIA Biotechnology Trading Up, Director Increases Holdings

MAIA Biotechnology to Present Cancer Treatment Research at FEBS Congress

MAIA Biotechnology signs stock purchase agreement to fund cancer research

MAIA Biotech Signs Clinical Supply Agreement with Roche

MAIA Biotech to Present THIO-101 Phase II Clinical Trial Results at Boston Conference

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

MAIA

LABU

SBIO

ARKG

MAIA Biotechnology has decided to terminate its at-the-market (ATM) sales agreement with H.C. Wainwright, effective seven business days after May 14, 2026. This decision ends the agreement made on February 14, 2024, under which the company raised approximately $5.68 million by selling 3,116,012 shares. The termination aligns with MAIA's capital markets strategy, and no termination fees were disclosed.

TradingView

iShares Global Healthcare

SPDR S&P Biotech

Health Care Select Sector SPDR

VG Health

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

MAIA Biotechnology to Terminate ATM Agreement With H.C. Wainwright After Raising $5.68M

Earnings Watch

MAIA Biotech | 10-Q: FY2026 Q1 Revenue: USD 0

MAIA Biotechnology (NYSEAMERICAN:MAIA) is set to release its Q1 2026 earnings on May 8, with analysts predicting a loss of $0.18 per share. The company previously reported a loss of $0.08 per share, exceeding expectations. MAIA's stock opened at $1.33, with a market cap of $80.69 million. Institutional investors hold 5.65% of the stock, with recent acquisitions by Marshall Wace LLP and Jane Street Group LLC. MAIA focuses on developing monoclonal antibody conjugates for cancer treatment and imaging.

Market Beat

MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday

MAIA Biotechnology has activated its first U.S. site for the Phase 2 expansion trial of THIO-101, targeting heavily pre-treated third-line NSCLC patients resistant to chemotherapy. The Summit Medical Group in New Jersey will facilitate U.S. patient access. The expansion is supported by a $2.3 million NIH grant, with plans to test ateganosine in combination with cemiplimab and as monotherapy at additional sites in 2026. MAIA's lead drug has FDA Fast Track designation, with previous data showing overall survival beyond 24 months in certain patients.

MAIA Biotechnology activates first U.S. site for THIO-101 Phase 2 expansion, NIH funds $2.3M

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | MAIA Stock News

StockTitan

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | MAIA Stock News

MAIA Biotechnology has raised $33 million to fund its Phase 3 trial of Ateganosine (THIO), a novel anticancer therapy targeting telomeres in non-small cell lung cancer (NSCLC). The trial aims to evaluate the drug's effectiveness in extending survival for patients who have exhausted standard treatments. The study will compare Ateganosine combined with checkpoint inhibitors against standard chemotherapy. This trial is crucial as lung cancer remains a leading cause of cancer deaths, and Ateganosine could offer new hope for patients with limited options. MAIA's stock closed at $1.24, up 3.33%.

nasdaq

MAIA Biotechnology Secures $33M To Power Phase 3 Trial

MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial

Tip Ranks

MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial

MAIA Biotech(MAIA.US)

MAIA Biotechnology to Terminate ATM Agreement With H.C. Wainwright After Raising $5.68M

MAIA Biotech | 10-Q: FY2026 Q1 Revenue: USD 0

MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday

MAIA Biotechnology activates first U.S. site for THIO-101 Phase 2 expansion, NIH funds $2.3M

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | MAIA Stock News

MAIA Biotechnology Secures $33M To Power Phase 3 Trial

MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial